Batavia Biosciences Partners with VBC and MEVAC to Boost Vaccine Manufacturing in Egypt

• Batavia Biosciences has announced a strategic partnership with Vaccine Biotechnology City (VBC) and MEVAC to strengthen vaccine manufacturing in Egypt.

• The collaboration focuses on Measles, Rubella, and Rotavirus vaccines, aiming to enhance vaccine accessibility in Africa and the Middle East.

Batavia Biosciences, a contract development and manufacturing organisation (CDMO) specialising in vaccines and viral vectors, has partnered with Vaccine Biotechnology City (VBC) and MEVAC to expand vaccine production in Egypt. The collaboration aims to localise the manufacturing of Measles, Rubella, and Rotavirus vaccines, supporting broader regional access to essential immunisations.

As part of the agreement, Batavia will transfer its proprietary technologies, analytical methods, and production systems to VBC and MEVAC. This initiative builds on a previous licensing agreement for Measles and Rubella vaccines, with ongoing negotiations for the Rotavirus vaccine. By equipping local manufacturers with advanced capabilities, the partnership seeks to position Egypt as a key vaccine producer for the Middle East and Africa.

VBC, established under Egypt’s national strategy to enhance vaccine self-sufficiency, leads the initiative with its focus on globally recognised manufacturing standards. MEVAC, a leader in animal health vaccine development, contributes its infrastructure and technical expertise. Both organisations operate under the Egyptian Vaccine Manufacturers Alliance (EVMA), which supports national vaccine production efforts.

Ahd Hamidi, Strategic Partnership Director at Batavia Biosciences, stated: “This collaboration reflects our mission to deliver affordable and accessible vaccine solutions to regions where they are most needed. By enabling local vaccine production, we aim to empower Egypt as a critical player in the fight against preventable diseases in Africa and beyond.”

The partnership is expected to accelerate vaccine availability and reduce reliance on imports. With discussions for Rotavirus vaccine production progressing, Batavia, VBC, and MEVAC will continue working together to enhance public health outcomes across Africa and the Middle East.